



Curis, Inc.  
Investor Relations Department  
4 Maguire Road  
Lexington, MA 02421  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: CRIS

Last Trade:	1.96
Trade Time:	10:33 AM ET Jul 28, 2017
Change:	0.00 (0.000%)
Day Range	1.93 - 2.05
52-Week Range	1.60 - 3.72
Volume	47,669

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jul 26, 2017*  
[Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017](#)

*Jul 5, 2017*  
[Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

*Jun 1, 2017*  
[Curis to Present at the Jefferies Healthcare Conference](#)

*May 25, 2017*  
[Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting](#)

*May 4, 2017*  
[Curis Reports First Quarter 2017 Financial Results](#)

## Upcoming Events [\[ View all \]](#)

*Aug 3, 2017 8:30 AM*  
[Q2 2017 Curis Inc Earnings Conference Call](#)

## Events [\[ View all \]](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 9, 2017*  
[Annual Report \(10-K\)](#)

*Apr 4, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*May 4, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)

*Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)